This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Green, L. J. Articles by Thornton, D. Search for Related Content PubMed PubMed Citation Articles by Green, L. J. Articles by Thornton, D.

Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-ß Inhibitor

Authors' Affiliations: ¹ Lilly Research Laboratories, Indianapolis, Indiana; ² The University of Texas M.D. Anderson Cancer Center, Houston, Texas; ³ Johns Hopkins Medical Institutions, Baltimore, Maryland; ⁴ University of California at Los Angeles Medical Center, Los Angeles, California; and ⁵ University of Colorado Cancer Center, Aurora, Colorado

Requests for reprints: Lisa J. Green, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis IN, 46285. Phone: 317-276-6048; Fax: 317-277-2934; E-mail: lisa.green{at}lilly.com.

Purpose: To evaluate the effects of the novel protein kinase C (PKC) inhibitor enzastaurin on intracellular phosphoprotein signaling using flow cytometry and to use this approach to measure enzastaurin effects on surrogate target cells taken from cancer patients that were orally dosed with this agent.

Experimental Design: The activity of PKC was assayed in intact cells using a modification of published techniques. The U937 cell line and peripheral blood mononuclear cells were stimulated with phorbol ester, fixed, permeabilized, and reacted with an antibody specific for the phosphorylated forms of PKC substrates. The processed samples were quantitatively analyzed using flow cytometry. The assay was validated for selectivity, sensitivity, and reproducibility. Finally, blood was obtained from volunteer cancer patients before and after receiving once daily oral doses of enzastaurin. These samples were stimulated ex vivo with phorbol ester and were assayed for PKC activity using this approach.

Results: Assay of U937 cells confirmed the selectivity of the antibody reagent and enzastaurin for PKC. Multiparametric analysis of peripheral blood mononuclear cells showed monocytes to be the preferred surrogate target cell. Day-to-day PKC activity in normal donors was reproducible. Initial results showed that five of six cancer patients had decreased PKC activity following enzastaurin administration. In a following study, a group of nine patients displayed a significant decrease in PKC activity after receiving once daily oral doses of enzastaurin.

Conclusion: An inhibition of surrogate target cell PKC activity was observed both in vitro and ex vivo after exposure to the novel kinase inhibitor, enzastaurin.

This article has been cited by other articles:

				J. Kim, Y.-L. Choi, A. Vallentin, B. S. Hunrichs, M. K. Hellerstein, D. M. Peehl, and D. Mochly-Rosen Centrosomal PKC{beta}II and Pericentrin Are Critical for Human Prostate Cancer Growth and Angiogenesis Cancer Res., August 15, 2008; 68(16): 6831 - 6839. [Abstract] [Full Text] [PDF]

				D. W. Hedley, S. Chow, C. Goolsby, and T. V. Shankey Pharmacodynamic Monitoring of Molecular-Targeted Agents in the Peripheral Blood of Leukemia Patients Using Flow Cytometry Toxicol Pathol, January 1, 2008; 36(1): 133 - 139. [Abstract] [Full Text] [PDF]

				R. K. Bowers, P. Marder, L. J. Green, C. L. Horn, A. L. Faber, and J. E. Thomas A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy Mol. Cancer Ther., September 1, 2007; 6(9): 2600 - 2607. [Abstract] [Full Text] [PDF]

				R. S. Herbst, Y. Oh, A. Wagle, and M. Lahn Enzastaurin, a Protein Kinase C{beta} Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4641s - 4646s. [Abstract] [Full Text] [PDF]

				K. Podar, M. S. Raab, J. Zhang, D. McMillin, I. Breitkreutz, Y.-T. Tai, B. K. Lin, N. Munshi, T. Hideshima, D. Chauhan, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl) Blood, February 15, 2007; 109(4): 1669 - 1677. [Abstract] [Full Text] [PDF]

				B. A. Teicher Protein kinase C as a therapeutic target. Clin. Cancer Res., September 15, 2006; 12(18): 5336 - 5345. [Full Text] [PDF]